T hree types of cancer account for at least 50% of new cases in each sex: prostate, lung, and colorectal cancers in males, and breast, lung, and colorectal cancers in females. Almost one-third of cancer deaths in men and almost one-quarter in women are due to lung cancer alone. Cancer is the leading cause of potential years of life lost (PYLL) for men and wom--en in Canada. 1 Simple, accessible and safe preventive therapies that will decrease the incidence and mortality of cancer are expected to have a great effect on public health.
Several in vitro studies showed antioxidant vitamins to have a significant protective effect against cancer. [2] [3] [4] In experimental animals deficiencies of vitamin E were associated with enhanced carcinogenesis, while supple--mentation of vitamin E inhibited tumor formation. 5, 6 The role of vitamin E in the prevention of cancer: a meta-analysis of randomized controlled trials Abdullah Alpha-tocopherol is the most common naturally occurring compound of vitamin E. The recommended dietary allowance of vitamin E is 15 mg daily for adult men and women. Each 1 mg of vitamin E equals to 1.5 IU of natural vitamin E and 2.2 IU of synthetic vitamin E. Vegetable oils, nuts, and green leafy vegetables are the main dietary sources of vitamin E.
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METHODS
Inclusion criteria
Data sources were randomized controlled trials (RCTs) in which outcomes related to cancer prevention that were associated with the intake of vitamin E supple--ments alone or with other supplements were compared to a control group (placebo or control). Participants in
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At least one of the following primary outcomes must have been reported: total mortality, cancer mor--tality, total incidence of cancer, or incidence of lung, stomach, esophageal, prostate, breast, urinary, hema--tological or thyroid cancers. Secondary outcomes were the role of high dose (≥300 mg/d) and low dose (<300 mg/d) vitamin E on the primary outcomes.
Search strategy for identification of studies
The following bibliographic databases were searched to identify the relevant primary studies: The Cochrane Controlled Trials Register (CCTR), MEDLINE, and EMBASE. A computerized search of MEDLINE was performed using the OVID platform, to search the MEDLINE database for articles published between January 1966 and June 2005, and the EMBASE da--tabase from 1980 to June 2005. The search strategy was conducted using the MeSH terms: "antioxidants" "vitamins", "vitamin E", "alpha-tocopherol", "tocopherol", "cancer", "prevention", and "randomized controlled tri-- als". These terms were used in various combinations. The Cochrane library was searched for relevant articles using the same search strategy. Relevant articles were retrieved through a manual review of references. No language restrictions were applied.
Study selection
All identified trials were reviewed independently by the two reviewers to assess methodological quality and de--termine whether trials should be included or excluded. Disagreement was resolved by discussion. All selected studies were published studies. The same two review--ers assessed the methodological quality of each trial ac--cording to Jadad score. 8 After independent evaluation, the two reviewers discussed the results for each study and any discrepancy was resolved by discussion.
Data abstraction and synthesis
Data were independently extracted by the same review--ers and cross-checked with discrepancies resolved by discussion. The Cochrane Statistics package RevMan, version 4.2 was used for data synthesis. Relative risk (RR) and risk difference (RD) with 95% confidence intervals were reported. If there was a statistically sig--nificant RD, the number needed to treat (NNT) and number needed to harm (NNH) were calculated.
Heterogeneity was tested using the Cochran Q sta--tistic with significance at P<0. 10 . In addition, we tested heterogeneity using the I2 method with a value greater than 50% considered to indicate substantial heteroge--neity. 9 Potential sources of heterogeneity of treatment effect were explored using pre-specified subgroup anal--ysis when there were sufficient studies to analyze the dose of vitamin E, the use of other vitamins with vi--tamin E, and study quality variability. Whenever there was statistically significant between-study heterogene--ity the weighted estimate of the typical treatment effect across trials (relative risk) was calculated using the ran--dom effects model to ensure robustness of the results.
Description of studies and methodological quality
Twelve trials, which included 167 025 individuals, met the inclusion criteria (Table 1 ). More than 76 000 (45%) of the participants were females. These tri--als were performed in many countries (Finland, Italy, Canada, China, UK, US, Denmark, Germany, Ireland, Netherlands, Norway, Spain, Sweden, Switzerland, and Mexico). Vitamin E dose varied between 50 mg/d to 800 mg/d. Study duration ranged between 510 days to 10 years. Two studies were open-label trials, but outcome assessment was blinded in these studies. 18, 20 All studies were analyzed using the intention to treat 
RESULTS
For vitamin E alone or with other supplements versus control (all 12 studies), vitamin E was associated with a significant reduction in the incidence of prostate cancer, but did not reduce the incidence of any other types of cancer (Table 2) . Four studies (including 71 759 indi--viduals) reported on the role of vitamin E in the pre--vention of prostate cancer ( Figure 1 , Table 3 ). [15] [16] [17] [18] [19] One study showed a statistically significant reduction in the incidence of prostate cancer in individuals receiving vi--tamin E supplements (RR 0.66; 95% CI 0.51, 0.84). 15 When all studies were combined there was a significant reduction in the incidence of prostate cancer (RR 0.85; 95% CI 0.74, 0.96, RD=-0.002, NNT=500, test for heterogeneity: P=0. 13, I2=47%) In studies with vitamin E alone versus control (6 studies) there was no statistically significant reduction in any of the outcomes (Table 2) . Two studies (includ--ing 24 114 individuals) evaluated the role of vitamin E alone in the prevention of prostate cancer (RR 0.86; 95% CI 0.70, 1.06). [15] [16] [17] [18] [19] In studies of vitamin E and other supplements vs. control, vitamin E was associated with a significant reduction in the incidence of prostate cancer, but did not reduce the incidence of any other types of cancer (Table 2) . Three studies (including 62 218 individuals) evaluated the role of vitamin E with other supplements in the prevention of prostate cancer (RR 0.79; 95% CI Table 3 . Data from four randomized, controlled trials that evaluated the role of vitamin e in the prevention of prostate cancer, and used in the pooled analysis (Figure 1 ). With a high dose of vitamin E (≥300 mg/d) there was no statistically significant reduction in any of the outcomes in studies that used a high dose of vitamin E (Table 2) . Two studies (including 30 077 individuals) evaluated the role of a high dose of vitamin E in the prevention of prostate cancer (RR 0.94; 95% CI 0.79, 1.11). 16, 19 With a low dose of vitamin E (<300 mg/d), vita--min E was associated with a significant reduction in the incidence of prostate cancer, but did not reduce the in--cidence of any other types of cancer that was available for analysis (Table 2) . Two studies (including 41 682 individuals) evaluated the role of low dose of vitamin E in the prevention of prostate cancer (RR 0.69; 95% CI 0.55, 0.87, NNT=380, test for heterogeneity: P=0.31, I2=1.6%). 15, 17 dIScuSSIon The methodological quality of the included trials was high. Vitamin E had no effect on total mortality, can--cer incidence and cancer mortality among the different groups of patients included in this meta-analysis. The only positive effect of vitamin E was in the reduction of the incidence of prostate cancer. This effect disappeared when we analyzed studies that evaluated the role of vitamin E alone; however, the sample size was insuffi--cient (21 634 male patients) to have enough power to detect a difference in the incidence of prostate cancer. A minimum of 32 000 participants is needed to detect a difference in the effect of vitamin E on the incidence of prostate cancer. 25, 26 The effect of vitamin E in the reduction of prostate cancer was statistically significant in studies that evalu--ated the role of vitamin E combined with other supple--ments. In this analysis we had a large sample size of 62 000 participants, which allowed enough power to detect a difference in the incidence of prostate cancer.
Symbols from
There was no statistically significant reduction of prostate cancer in studies that used high dose of vitamin E (>300 mg); however, in this analysis the sample size was insufficient (22 515 male patients) to have enough power to detect a difference in the incidence of prostate cancer. There was a statistically significant reduction of prostate cancer in studies that used a low dose of vita--min E (<300 mg) and there was enough power to de--tect a difference in the incidence of prostate cancer.
Vitamin E supplementation results in a minimum of 0.2% absolute reduction in the incidence of prostate cancer, which can be translated into a a number needed to treat (NNT) of 500. This effect of vitamin E is im--portant as prostate cancer is the leading form of cancer diagnosed in men, affecting 0.7% of the male popula--tion1. Vitamin E was well tolerated in all of the includ--ed trials. Previous meta-analysis showed that vitamin E did not affect the rate of coronary and cerebrovascular events. 27, 28 In conclusion, vitamin E supplementation can be used for the prevention of prostate cancer among high risk groups, including individuals >55 years old, pa--tients with elevated prostate specific antigen (PSA), African Americans, and patients with family history of prostate cancer. The results of the SELECT trial and other ongoing trials (Table 4) will provide more precise answers on the role of vitamin E in the prevention of prostate cancer. June 2-6, 2006 . The authors declare no conflict of interest.
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